

CLAIMS

1. A pharmaceutical aerosol foam composition including an effective amount of a pharmaceutically active ingredient
an occlusive agent;
an aqueous solvent; and
an organic cosolvent

the pharmaceutically active ingredient being insoluble in both water and the occlusive agent;
the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.

2. A pharmaceutical aerosol foam composition according to Claim 1, wherein the water insoluble pharmaceutically active ingredient is selected from one or more of the group consisting of an analgesic, anti-inflammatory agent, antifungal, antibacterial, anaesthetic, xanthine, sex hormone, antiviral, antipruritic, antihistamine or corticosteroid.

3. A pharmaceutical aerosol foam composition according to Claim 2, wherein the pharmaceutically active ingredient is a corticosteroid selected from one or more of the group consisting of, betamethasone valerate, and clobetasol propionate.

4. A pharmaceutical aerosol foam composition according to Claim 1, wherein the pharmaceutically active ingredient is present in amounts of from approximately 0.005% by weight to approximately 10% by weight, based on the total weight of the pharmaceutical mousse composition.

5. A pharmaceutical aerosol foam composition according to Claim 1, wherein the occlusive agent is selected from one or more of the group consisting of mineral oils and greases, long chain acids, animal fats and greases, vegetable fats and greases and water insoluble polymers.

Sub B6
6. [A pharmaceutical aerosol foam composition] according to Claim 5, wherein the occlusive agent includes petrolatum.

7. A pharmaceutical aerosol foam composition according to Claim 1, wherein the occlusive agent is present in an amount of approximately 55% by weight or less, based on the total weight of the composition.

8. A pharmaceutical aerosol foam composition according to Claim 7, wherein the occlusive agent is present in an amount of approximately 10 to 50% by weight, based on the total weight of the composition.

9. A pharmaceutical aerosol foam composition according to Claim 1, further including an effective amount of an emulsifier and/or surfactant.

10. A pharmaceutical aerosol foam composition according to Claim 9, wherein the emulsifier or surfactant is selected from any one or more of the group consisting of non-ionic, cationic or anionic surfactants, fatty alcohols, fatty acids and fatty acid salts thereof.

11. A pharmaceutical aerosol foam composition according to Claim 10, wherein the emulsifier includes a mixture of sorbitan monostearate and polysorbate 60.

12. A pharmaceutical aerosol foam composition according to Claim 9, wherein the surfactant component is present in an amount of from approximately 1 to 15% by weight, based on the total weight of the composition.

13. A pharmaceutical aerosol foam composition according to Claim 1, wherein the aqueous solvent is present in an amount of from approximately 25 to 95% by weight, based on the total weight of the composition.

14. A pharmaceutical aerosol foam composition according to Claim 13, wherein the organic cosolvent is present in an amount of from approximately 0.25% by weight to 50% by weight, based on the total weight of the composition.

00195-1111-00

17. A pharmaceutical aerosol foam composition according to Claim 16, wherein the aerosol propellant is a hydrocarbon and is present in an amount of from approximately 2.5 to 20% by weight, based on the total weight of the composition.

an organic cosolvent.

the occlusive agent being present in an amount sufficient to form an occlusive layer on the skin, in use.

19. A pharmaceutical aerosol foam composition substantially as hereinbefore described with reference to any one of the examples.

[illegible]

Sub
BT

Ad
B8